Monday 19th October 2020 |
Text too small? |
• Second phase of national clinical trial in Sichuan Province reported outstanding results
• Conducted by China Obstetrics and Gynaecology Association (COGA) a peak gynaecology body in China.
• Trial conducted across 14 hospitals with 1,243 patients participating
• Both sensitivity and specificity targeting pre-cancerous and cancerous cervical cells performed in aggregate better than other screening methods (see below table)
Truscreen Group Limited (NZX: TRU ) (Truscreen or Company) is pleased to advise results from The China Obstetrics and Gynaecology Association (COGA) ongoing national clinical trial that will screen over 20,000 women in 100 top-tier public hospitals across 10 provinces in China. The COGA evaluation compares the TruScreen technology to Liquid Based Cytology (LBC), and HPV DNA testing (HPV) and targets a nationwide consensus on Truscreen technology application in China as the main outcome of this large-scale trial.
See the link below for more details:
Sichuan Province Trial Confirms Truscreen Technology
Source: Truscreen Group Limited
No comments yet
Fonterra appoints permanent COO
Manawa Energy FY24 Annual Results & Webcast Details
Seeka Provides the Results of Meeting - ASM
April 19th Morning Report
PGW Guidance Update
CNU - Commerce Commission releases draft expenditure decision
Spark announces departure of Product Director
TGG - T&G appoints new Director
April 18th Morning Report
SKC - APPOINTMENT OF CHIEF EXECUTIVE OFFICER